Eledon Pharmaceuticals (ELDN)
Develops tegoprubart for transplant rejection and CD40L-linked immune disease.
Something off on this page? Send us feedback.
Develops the anti-CD40L antibody tegoprubart across kidney, islet, liver, and xenotransplant programs, with ALS work also in scope. Operations are concentrated in the United States, and the business remains pre-commercial with a single reportable segment centered on tegoprubart.
Develops tegoprubart, an IgG1 anti-CD40L antibody, as its sole reportable-segment focus after the Anelixis acquisition shifted the company away from legacy ENT assets. Current programs center on kidney transplantation, with islet cell, liver, xenotransplantation, and ALS-related work also in scope.
Operates from Irvine, California, with R&D activity in Burlington, Massachusetts, so the footprint is concentrated in the United States while kidney-transplant studies have included global clinical sites. The pipeline depends on CD40L biology as a way to modulate immune signaling around transplanted organs.
Has no approved commercial products or product-sales revenue to date. The business depends on successful tegoprubart trials, regulatory alignment for later-stage development, financing, and eventual commercialization.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| Jul 21, 2026 | Rodman & Renshaw | Initiate | Buy | |
| Mar 16, 2026 | Leerink Partners | Target | $5 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $88.8M · Total debt $467.0K · Total assets $126.1M · Shareholders' equity $72.0M
- Revenue
- $0
- Operating income
- −$22.9M
- Net income
- −$31.6M
No dividends on record.
| Institutions168 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 57.56% | 46.77M shares | |
| Insiders10 holders · as of Aug 4, 2026 | 1.30% | 1.06M shares | |
| Otherremainder | ≈ 41.14% | 33.43M shares |
81.26M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
BVF Inc/ILInstitution | 7.74% | 6.29M | 13Fas of Jun 30, 2026 |
Biotechnology Value Fund L PInstitution | 6.62% | 5.38M | 13Gfiled May 15, 2026 ↗ |
BlackRock, Inc.Institution | 6.31% | 5.12M | 13Fas of Jun 30, 2026 |
Defilade Capital Management, L.P.Institution | 4.34% | 3.53M | 13Fas of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.21% | 3.42M | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
No open-market trades in the last 12 months.
- Bristol-Myers Squibb
Approved costimulation blocker for kidney-transplant rejection
- Novartis (ADR)
Myfortic and Simulect anchor adjacent kidney-transplant regimens
- Sanofi (ADR)
Large-scale anti-CD40L developer with frexalimab
- Tonix Pharmaceuticals
Early anti-CD40L transplant candidate targeting kidney rejection
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Eledon Pharmaceuticals | $3.15 | +5.53% | $230.8M | — | — | — | — |
| Bristol-Myers Squibb | $67.38 | −0.40% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| Novartis (ADR) | $162.45 | +0.01% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| Sanofi (ADR) | $44.52 | +0.12% | $106.78B | 78.2 | — | 1.9 | +11.2% |
| Tonix Pharmaceuticals | $13.65 | +2.02% | $213.3M | — | — | 7.3 | +577.9% |
| Median | 24.5 | 14.0 | 4.2 | +8.5% |